Quick answer: Low testosterone in women — defined as total testosterone below 15–20 ng/dL or free testosterone below 0.3 ng/dL — causes low libido (hypoactive sexual desire disorder), persistent fatigue, muscle loss, increased visceral fat, mood changes, and cognitive decline. It is rarely tested because standard “female hormone panels” omit testosterone entirely. The most evidence-based natural approach: resistance training (raises testosterone 15–25% and reduces SHBG), DHEA supplementation 25–50 mg/day (the most evidence-based precursor approach in women with documented DHEA-S deficiency), and addressing the oral contraceptive SHBG effect that masks low free testosterone despite normal total testosterone.
Why Testosterone Matters for Women
Testosterone in women is produced primarily by the ovaries and adrenal glands, with smaller contributions from peripheral conversion of DHEA. While female testosterone levels are 10–15% of male levels (15–70 ng/dL vs. 300–1,000 ng/dL), testosterone plays critical roles in female physiology: libido and sexual arousal (the most well-established clinical use), lean muscle mass maintenance, bone density, mood regulation, cognitive function (testosterone receptors are distributed throughout the hippocampus and prefrontal cortex), and energy. Women’s testosterone begins declining in the late 20s and falls approximately 50% by menopause — a trajectory that begins far earlier than estrogen decline, which is concentrated in the perimenopausal transition.
The clinical challenge is that low testosterone in women is systematically undertested. Standard gynecological hormone panels measure estradiol, FSH, and LH — but omit testosterone. When testosterone is measured, total testosterone is reported without free testosterone or SHBG — missing the critical issue that many women have “normal” total testosterone with suppressed free testosterone (the biologically active fraction) due to elevated SHBG from oral contraceptive use or estrogen therapy. A complete evaluation requires: total testosterone, free testosterone (by equilibrium dialysis, not direct immunoassay), SHBG, and DHEA-S.
The Oral Contraceptive Problem: Hidden Low Free Testosterone
Oral contraceptive pills (OCPs) containing ethinylestradiol increase hepatic SHBG synthesis by 3–4x. SHBG (sex hormone-binding globulin) binds testosterone tightly, reducing the free fraction available to act on receptors. Women on OCPs can have total testosterone in the “normal” range while free testosterone is 40–60% lower than pre-OCP levels — a state of functional testosterone deficiency that is completely invisible on standard panels measuring only total testosterone. This mechanism explains the well-documented association between OCP use and reduced libido, genital arousal, and sexual satisfaction — effects that can persist for months to years after OCP discontinuation because SHBG elevation partially persists (the “SHBG setpoint” phenomenon).
For women with persistent low libido and sexual dysfunction after OCP discontinuation, measuring both total testosterone and free testosterone (or calculating it from total T and SHBG) is essential. Normalizing free testosterone — rather than total testosterone — is the therapeutic target. Approaches include: discontinuing or switching to non-estrogen-containing contraception (progestin IUD, barrier methods), resistance training (which reduces SHBG 10–20%), and DHEA supplementation to raise the testosterone precursor pool.
Causes of Low Testosterone in Women
Age-related decline: Ovarian and adrenal testosterone production declines progressively from the late 20s. Surgical menopause (oophorectomy) causes an immediate 50% reduction in testosterone, as the ovaries contribute approximately half of female testosterone. Natural menopause produces a more gradual decline, though the transition period involves significant variability.
HPA axis dysfunction and cortisol excess: DHEA and testosterone share biosynthetic precursors with cortisol in the adrenal gland. Under chronic stress, pregnenolone (the master steroid precursor) is shunted toward cortisol synthesis at the expense of DHEA and testosterone production — the “pregnenolone steal” or cortisol dominance phenomenon. Chronic HPA axis activation is one of the most common causes of low DHEA-S and secondary low testosterone in premenopausal women. Testing DHEA-S alongside testosterone identifies this pattern — low DHEA-S with low testosterone suggests adrenal precursor depletion as the root cause.
Very low dietary fat: Cholesterol is the precursor for all steroid hormones. Women following very low-fat diets (below 20% of calories from fat) consistently show lower total and free testosterone levels. This is a modifiable cause: increasing dietary fat from healthy sources (EVOO, avocado, fatty fish, eggs) to at least 30–35% of calories supports adequate steroid hormone synthesis substrate.
Hypothyroidism: Thyroid hormone deficiency reduces the ovarian response to LH stimulation, decreases testosterone synthesis, and increases SHBG — a triple mechanism that depresses free testosterone. Addressing hypothyroidism (TSH below 2.0, optimal free T3 in the upper third of range) often improves testosterone levels without direct testosterone intervention.
The Natural Testosterone Optimization Protocol for Women
Resistance Training — First and Most Effective
Resistance training 3–4 times per week is the most powerful non-pharmacological intervention for female testosterone optimization. The mechanisms: acute testosterone release in response to muscle contraction and mechanical stress, SHBG reduction (10–20% with consistent training), visceral fat reduction (which reduces aromatase activity — the enzyme that converts testosterone to estrogen), and improved hypothalamic GnRH pulsatility that supports ovarian function. Studies in premenopausal and postmenopausal women show 15–25% increases in bioavailable testosterone with 8–12 weeks of consistent resistance training. The protocol: compound movements (squats, deadlifts, rows, presses) at 70–85% 1-rep maximum, 3–5 sets per movement, progressive overload over time.
DHEA Supplementation
DHEA (dehydroepiandrosterone) is the most evidence-based natural precursor approach for female testosterone. At 25–50 mg/day, DHEA supplementation consistently raises both DHEA-S and free testosterone in women with documented DHEA-S deficiency (below 100 μg/dL is generally considered deficient). A Cochrane review of DHEA for sexual dysfunction in postmenopausal women found significant improvements in sexual interest, arousal, lubrication, and orgasm. For premenopausal women with documented low DHEA-S on testing, 25 mg/day is the starting dose — lower than postmenopausal women because the premenopausal ovary still contributes more to testosterone production. DHEA-S monitoring at 8–12 weeks guides dose adjustment. Note: DHEA should be used under physician supervision as it can convert to both testosterone and estrogen — the conversion pattern varies by individual aromatase activity.
Zinc and Vitamin D
Zinc (30 mg/day as zinc glycinate) supports testosterone synthesis by serving as a cofactor for 5-alpha-reductase (which converts testosterone to the more potent DHT) and for the androgen receptor signaling pathway. Zinc deficiency directly impairs testosterone production, and deficiency is common in women following plant-heavy diets due to phytate binding. Vitamin D levels above 50 ng/mL associate with higher testosterone and better SHBG regulation in cross-sectional studies — the vitamin D receptor is expressed in ovarian cells and modulates steroidogenesis. Supplementing to 50–70 ng/mL (typically 5,000 IU/day) is appropriate for most deficient women.
Ashwagandha KSM-66 for HPA-Related Testosterone Suppression
For women with the stress/HPA-driven low testosterone pattern (low DHEA-S + high or previously high cortisol + stress history), ashwagandha KSM-66 at 300 mg twice daily addresses both sides of the equation simultaneously: reducing cortisol (documented 23–28% reduction in RCTs) and increasing DHEA simultaneously. A 2019 RCT specifically in women found ashwagandha significantly increased testosterone levels and sexual function scores compared to placebo. The mechanism: cortisol reduction frees pregnenolone for DHEA and testosterone synthesis rather than cortisol.
When to Consider Testosterone Replacement Therapy
Testosterone replacement therapy (TRT) in women is FDA-approved in no specific formulation, but is widely prescribed off-label as compounded testosterone cream, gel, or pellets for documented testosterone deficiency with clinical symptoms. The Global Consensus Position Statement on Female Testosterone (2019, endorsed by 11 international endocrinology and gynecology societies) recommends testosterone therapy specifically for hypoactive sexual desire disorder (HSDD) with documented low testosterone, after ruling out other causes of low libido. The evidence base: 36 RCTs totaling over 8,000 women support testosterone for HSDD, with consistent improvements in sexual desire, arousal, satisfaction, and frequency. The target for TRT in women is free testosterone in the upper half of the female reference range — not male-level testosterone, which produces androgenic side effects. Pellet implants, which can produce supraphysiological levels, require careful monitoring.
Comprehensive hormone evaluation — total testosterone, free testosterone, SHBG, DHEA-S, and complete thyroid panel — is the starting point for any woman experiencing symptoms of testosterone deficiency. Call our office at (810) 206-1402 to schedule a hormonal health assessment with individualized natural optimization and replacement guidance.
Frequently Asked Questions
What are the symptoms of low testosterone in women?
The most common symptoms are hypoactive sexual desire disorder (HSDD) — reduced sexual interest, arousal, and satisfaction — along with persistent fatigue unresponsive to adequate sleep, loss of muscle mass and strength, increased body fat (particularly visceral), mood changes including depression and irritability, cognitive difficulties (brain fog, reduced concentration), and reduced bone density. These symptoms overlap significantly with other hormonal conditions, making testosterone measurement essential for accurate diagnosis. Many women with low testosterone are diagnosed with depression or “burnout” without ever having testosterone tested.
What causes low testosterone in women?
The primary causes are: age-related ovarian decline (testosterone begins declining in the late 20s, falling 50% by menopause), oral contraceptive use (which increases SHBG by 3-4x, reducing free testosterone by 40-60% even when total T is normal), HPA axis dysfunction from chronic stress (cortisol competes directly with testosterone precursors via the pregnenolone steal), very low dietary fat intake (cholesterol is the precursor for all steroid hormones), and surgical menopause (oophorectomy causes immediate 50% testosterone reduction). Hypothyroidism simultaneously reduces testosterone synthesis and increases SHBG, compounding the deficiency.
How do you test testosterone in women?
The optimal panel is: total testosterone, free testosterone (calculated from total T and SHBG, or measured by equilibrium dialysis — NOT the direct immunoassay which is inaccurate at low female ranges), SHBG (which determines how much total T is biologically active), DHEA-S (the precursor pool), and morning cortisol. LC-MS/MS (liquid chromatography-mass spectrometry) is the gold standard for female testosterone measurement. Reference ranges for women: total T 15–70 ng/dL, free T 0.3–1.9 ng/dL, though optimal function typically requires the upper half of this range.
Can women increase testosterone naturally?
Yes. The most effective natural interventions are: resistance training 3-4 sessions/week (increases bioavailable testosterone 15-25% and reduces SHBG), DHEA supplementation 25-50 mg/day (raises both DHEA-S and free testosterone in women with documented deficiency), zinc 30 mg/day (supports testosterone synthesis cofactors), vitamin D correction to 50+ ng/mL (associates with higher testosterone and better SHBG regulation), dietary fat adequacy (minimum 30% of calories from fat for steroid hormone synthesis), and ashwagandha KSM-66 300 mg twice daily for HPA-driven cases (reduces cortisol and increases DHEA simultaneously).